Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,080 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Transplantation Clear all
Withdrawn Phase 2 Interventional

Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

NCT00878761
View directory record Official record
Conditions
Chronic Allograft Dysfunction
Interventions
STX-100
Biological
Lead sponsor
Stromedix, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 10, 2026, 6:50 AM EDT
Terminated No phase listed Observational

CEC/EPC and Cardiovascular Risk in Renal Transplant Recipients

NCT00365833
View directory record Official record
Conditions
Transplantation, Kidney, Cardiovascular Abnormalities, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2011 · Synced Oct 10, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation

NCT01279538
View directory record Official record
Conditions
Kidney Transplantation
Interventions
bleselumab, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 10, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Protection After Transplant Pilot Study

NCT04969263
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
BNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 10, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 10, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rituxan
Biological
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 10, 2026, 6:50 AM EDT
Withdrawn No phase listed Observational

BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach

NCT02758288
View directory record Official record
Conditions
BK Virus Infection, BK Virus Nephropathy
Interventions
New Protocol - BK viremia or BK virus nephropathy, Standard Protocol - BK viremia or BK virus nephropathy
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 10, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

NCT00374803
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Mycophenolic Acid (Myfortic)
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 10, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

NCT00369382
View directory record Official record
Conditions
Graft Rejection, Kidney Failure
Interventions
cyclosporine or tacrolimus, sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 10, 2026, 6:50 AM EDT
Recruiting Not applicable Interventional

Structured Program of Exercise for Recipients of Kidney Transplantation

NCT04954690
View directory record Official record
Conditions
Kidney Transplant; Complications, Dialysis; Complications, Physical Disability, Frailty Syndrome
Interventions
Structured Program of exercise for Recipients of Kidney Transplantation (WC), Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG), Usual Care
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 10, 2026, 6:50 AM EDT
Completed No phase listed Observational Results available

DBS for Home Monitoring in Children With Kidney Transplantation

NCT01931397
View directory record Official record
Conditions
Kidney Disease
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 10, 2026, 6:50 AM EDT
Completed No phase listed Observational

CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients

NCT00227045
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2007 · Synced Oct 10, 2026, 6:50 AM EDT
Completed No phase listed Observational

Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients

NCT01558037
View directory record Official record
Conditions
Awaiting Organ Transplant, Infection in Solid Organ Transplant Recipients
Interventions
Not listed
Lead sponsor
Michael Ison
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 10, 2026, 6:50 AM EDT
Completed No phase listed Observational

Multidimensional System to Dynamically Predict Graft Survival After Kidney Transplantation

NCT04258891
View directory record Official record
Conditions
Kidney Transplant Failure
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Timeline
2004 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 10, 2026, 6:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

NCT00767897
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis
Interventions
Human Papillomavirus Vaccine
Drug
Lead sponsor
Indiana University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 10, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Results available

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

NCT00698685
View directory record Official record
Conditions
Leukemia, Lymphoma, Hodgkin's Disease, Hematologic Neoplasms, Multiple Myeloma, Carcinoma, Renal Cell
Interventions
Pentostatin, Alemtuzumab, Allogeneic hematopoietic stem cell transplantation
Drug · Biological · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 10, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168
View directory record Official record
Conditions
Kidney Diseases
Interventions
YSPSL, placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 10, 2026, 6:50 AM EDT
Recruiting No phase listed Observational

The KidneyCARE (Community Access to Research Equity) Study

NCT05497518
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Kidney Transplant
Interventions
Observational study - registry
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2070
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 10, 2026, 6:50 AM EDT
Withdrawn Phase 4 Interventional

The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone

NCT02030314
View directory record Official record
Conditions
Resistant Hypertension in Kidney Transplant Patients
Interventions
Chlorthalidone
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 10, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

NCT00806676
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Gardasil® Vaccine (FDA-approved vaccination regimen)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
9 Years to 21 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 10, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
View directory record Official record
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 10, 2026, 6:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT06625190
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma, Wilms Tumor
Interventions
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
Device · Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Months to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 10, 2026, 6:50 AM EDT
Recruiting Phase 3 Interventional

Shingrix in Renal Transplant Recipients

NCT04128189
View directory record Official record
Conditions
Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation, Herpes Zoster (HZ)
Interventions
Shingrix
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 10, 2026, 6:50 AM EDT
Completed No phase listed Observational

Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease

NCT00904579
View directory record Official record
Conditions
Immunocompromised Host, Organ Transplantation, Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 100 Years
Enrollment
19,929,901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 10, 2026, 6:50 AM EDT